Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Dissent: Guidelines for Management of Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Incorporating Economic Evidence in Clinical Guidelines.

Annals of internal medicine·2026
Same author

Commensal Bacteria: An Under-recognized Cause of Pneumonia.

The Journal of infectious diseases·2026
Same author

Diagnosis versus Hypothesis: Optimal Terminology to Enhance Clinical Reasoning.

Southern medical journal·2025
Same author

Higher-Valent Pneumococcal Conjugate Vaccines-Perspective for 2026.

JAMA internal medicine·2025
Same journal

A rocking biologic prosthetic valve: <i>Cutibacterium acnes</i> prosthetic valve endocarditis.

Hospital practice (1995)·2026
Same journal

Diagnostic accuracy of the Wells score versus duplex ultrasound for deep vein thrombosis in a Ghanaian cohort.

Hospital practice (1995)·2026
Same journal

Examining the frequency and factors related to the occurrence of deep vein thrombosis (DVT) in patients undergoing posterior fixation of the lumbosacral spine (PSF).

Hospital practice (1995)·2025
Same journal

The impact of hospitalist experience on patient outcomes: a retrospective cohort analysis at an academic medical center.

Hospital practice (1995)·2025
Same journal

The efficacy of melatonin as a preoperative anxiolytic in real-world setting: a randomized controlled trial.

Hospital practice (1995)·2025
Same journal

Antibiotic prescription patterns among hospitalized patients with influenza: a cross-sectional study in a tertiary referral hospital in Iran.

Hospital practice (1995)·2025
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

New modalities in treating pneumococcal pneumonia.

Daniel M Musher1

  • 1Infectious Disease Section, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. dmusher@bcm.edu

Hospital Practice (1995)
|May 18, 2011
PubMed
Summary
This summary is machine-generated.

Adjunctive therapies like macrolides, statins, and aspirin may improve outcomes for severe pneumococcal pneumonia. Activated protein C is recommended for select patients with severe sepsis and organ failure.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pharmacology

Background:

  • Pneumococcal pneumonia causes significant mortality despite advanced medical care.
  • Early diagnosis of community-acquired pneumonia (CAP) is increasingly feasible.
  • Adjunctive therapies are being investigated to improve outcomes for Streptococcus pneumoniae infections.

Purpose of the Study:

  • To review adjunctive measures for hospitalized patients with pneumococcal pneumonia.
  • To evaluate the efficacy of various treatments beyond standard antibiotics.
  • To identify potential therapies that reduce mortality and complications.

Main Methods:

  • Review of available data on adjunctive treatments for pneumococcal pneumonia.
  • Analysis of subgroup data from major studies on severe sepsis.
  • Examination of retrospective studies on anti-inflammatory agents.

Main Results:

  • Macrolides combined with beta-lactam antibiotics are favored due to macrolides' immunomodulatory effects.
  • Activated protein C may benefit patients with severe sepsis and organ failure (APACHE II score > 25).
  • Statins and aspirin show potential benefits by reducing inflammation and myocardial infarction risk; corticosteroids lack convincing evidence.

Conclusions:

  • Combination therapy with macrolides and beta-lactams is recommended.
  • Activated protein C, statins, and aspirin are potential adjunctive treatments for specific patient groups.
  • Corticosteroids do not appear beneficial and may worsen outcomes in pneumococcal pneumonia.